We are establishing a number of resources to give scientists access to the first-rate technology and expertise required for measuring epigenetic processes on the genomic scale, and for developing novel reagents and approaches to interrogate the state of chromatin.
Epigenetics Technology Innovation Lab
Epigenetic aberrations play important roles in cancer development and progression. The Epigenetics Technology Innovation Lab provides MSK physicians and scientists with state-of-the-art epigenomic profiling techniques to understand how epigenetic processes contribute to cancer. Current available techniques include ChIP and Omni-ATAC. CUT&RUN and other experimental methods will be available soon.
- ChIP - enables researchers to analyze protein interaction with DNA. It is a powerful method to selectively enrich for DNA sequences bound by a particular protein using its specific antibody. Coupled with NGS sequencing, it can be used to identify genome-wide binding sites of DNA-associated proteins of interest. We currently provide TF and histone ChIP.
- Omni-ATAC - enables researchers to assess chromatin accessibility in cells or tissues. It is an improved ATAC protocol with reduced mitochondria DNA contamination and substantial improvement of signal-to-background ratio. Coupled with NGS sequencing, it can be used for genome-wide mapping of the regulatory landscape of chromatin.
We highly recommend you meet with our staff before submitting a project.
Computational Epigenetics Lab
The primary objective is to leverage next generation sequencing data to provide novel insights into cancer epigenetics, with the goal of deciphering both how cancers arise and how to treat them. To this end, we’ve established a group of experts in computational biology and bioinformatics who specialize in analyzing and integrating epigenomic data. Working together with other groups at MSK — including computational scientists in the Computational Biology Program, the Computational Oncology Service, and the Bioinformatics Core Facility — this core team will help establish methods for comprehensive genomic and epigenomic assessment of cancer cells.
Preclinical Interface Platform
CER scientists will work closely with MSK’s core facilities for Antitumor Assessment and RNA Interference to create a platform to develop preclinical models, new therapeutic approaches, and chemical biology tools to target tumors at the epigenetic level. The platform will allow us to establish libraries of potent and specific small molecules that target chromatin-regulatory complexes. It will also help guide preclinical studies of promising molecules that have the potential to ultimately be moved to clinical assessment in patients.